109 related articles for article (PubMed ID: 1603993)
1. [Computed tomography and tumor markers as diagnostic alternatives to second-look surgery in the treatment of malignant ovarian tumors].
La Fianza A; Campani R; Dore R; Babilonti L; Torretta L
Radiol Med; 1992 Apr; 83(4):374-82. PubMed ID: 1603993
[TBL] [Abstract][Full Text] [Related]
2. Abdominal recurrence of ovarian cancer: value of abdominal MR in patients with positive CA125 and negative CT.
Balestreri L; Bison L; Sorio R; Morra A; Campagnutta E; Morassut S
Radiol Med; 2002; 104(5-6):426-36. PubMed ID: 12589264
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation on non invasive diagnostic tests for the second look in epithelial ovarian cancer].
García Enguídanos A; Crespo Azanza E; Díaz Recaséns J; Lobo Samper F; Jorge Herrero JA; Sáinz de la Cuesta Abbad R
Rev Clin Esp; 1998 Aug; 198(8):502-5. PubMed ID: 9774878
[TBL] [Abstract][Full Text] [Related]
4. [The value of preoperative diagnosis before second-look laparotomy in ovarian cancer].
Meden H; Rath W; Ohlmeyer D
Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):101-5. PubMed ID: 2180783
[TBL] [Abstract][Full Text] [Related]
5. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
Vardi JR; Tadros GH; Foemmel R; Shebes M
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the role of second-look surgery in ovarian cancer.
Chambers SK; Chambers JT; Kohorn EI; Lawrence R; Schwartz PE
Obstet Gynecol; 1988 Sep; 72(3 Pt 1):404-8. PubMed ID: 3405557
[TBL] [Abstract][Full Text] [Related]
8. [Serum CA 125 values and histologic findings at the time of second-look laparotomy in ovarian cancer].
Meier W; Stieber P; Fateh-Moghadam A; Eiermann W; Hepp H
Geburtshilfe Frauenheilkd; 1988 May; 48(5):331-3. PubMed ID: 3165078
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for second-look laparotomy in the management of malignant germ cell tumors of the ovary? Experience at Institut Gustave Roussy.
Culine S; Lhomme C; Michel G; Leclere J; Duvillard P; Droz JP
J Surg Oncol; 1996 May; 62(1):40-5. PubMed ID: 8618400
[TBL] [Abstract][Full Text] [Related]
10. [Predictive value of the tumor marker combination CA-125 and beta-2-microglobulin in ovarian cancer].
Hernádi Z; Molnár V; Juhász B; Pólka R; Margitai B
Zentralbl Gynakol; 1992; 114(1):6-9. PubMed ID: 1585745
[TBL] [Abstract][Full Text] [Related]
11. ["Second-look" surgery and diagnostic laparoscopy in the combined and comprehensive therapy of patients with ovarian cancer].
Gulo EI; Maksimov SIa; Livshits MA; Shcherbakov AM
Vopr Onkol; 1998; 44(2):205-10. PubMed ID: 9615829
[TBL] [Abstract][Full Text] [Related]
12. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
Chen DX; Schwartz PE; Li FQ
Obstet Gynecol; 1990 Apr; 75(4):701-4. PubMed ID: 2179784
[TBL] [Abstract][Full Text] [Related]
13. [Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?].
Sevelda P; Rosen A; Barrada M; Gober S; Vavra N; Salzer H
Gynakol Rundsch; 1990; 30 Suppl 1():210-1. PubMed ID: 2079273
[No Abstract] [Full Text] [Related]
14. [Negative second-look laparatomy in ovarian cancers. Survival analysis and prognostic factors from 64 cases treated at the Gustave Roussy Institute].
Pautier P; Rey A; Michel G; Castaigne D; Rochard F; Duvillard P; Haie-Meder C; Curcio P; Benedetti-Richard L; Lhommé C
Bull Cancer; 1997 Feb; 84(2):147-54. PubMed ID: 9180837
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between serum CA125 level and second-look findings in ovarian cancers].
Liu LY
Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):287-9. PubMed ID: 1327702
[TBL] [Abstract][Full Text] [Related]
16. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
Göcze P; Vahrson H
Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
[TBL] [Abstract][Full Text] [Related]
17. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
18. [Second-look laparotomy in epithelial ovarian cancer: an evaluation of 23 cases].
Liu LY
Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):77-9, 123. PubMed ID: 2364794
[TBL] [Abstract][Full Text] [Related]
19. The controversial 'second-look' laparotomy.
Bokhman YaV ; Vinokurov VL; Gulo EI
Acta Obstet Gynecol Scand Suppl; 1992; 155():79-83. PubMed ID: 1502895
[TBL] [Abstract][Full Text] [Related]
20. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
